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Abstract
Objectives: To identify associations between specific WHO stage 3 and 4 conditions diagnosed after ART initiation and all
cause mortality for patients in resource-limited settings (RLS).
Design, Setting: Analysis of routine program data collected prospectively from 25 programs in eight countries between
2002 and 2010.
Subjects, Participants: 36,664 study participants with median ART follow-up of 1.26 years (IQR 0.55–2.27).
Outcome Measures: Using a proportional hazards model we identified factors associated with mortality, including the
occurrence of specific WHO clinical stage 3 and 4 conditions during the 6-months following ART initiation.
Results: There were 2922 deaths during follow-up (8.0%). The crude mortality rate was 5.41 deaths per 100 person-years
(95% CI: 5.21–5.61). The diagnosis of any WHO stage 3 or 4 condition during the first 6 months of ART was associated with
increased mortality (HR: 2.21; 95% CI: 1.97–2.47). After adjustment for age, sex, region and pre-ART CD4 count, a diagnosis of
extrapulmonary cryptococcosis (aHR: 3.54; 95% CI: 2.74–4.56), HIV wasting syndrome (aHR: 2.92; 95%CI: 2.21 -3.85), non-
tuberculous mycobacterial infection (aHR: 2.43; 95% CI: 1.80–3.28) and Pneumocystis pneumonia (aHR: 2.17; 95% CI 1.80–
3.28) were associated with the greatest increased mortality. Cerebral toxoplasmosis, pulmonary and extra-pulmonary
tuberculosis, Kaposi’s sarcoma and oral and oesophageal candidiasis were associated with increased mortality, though at
lower rates.
Conclusions: A diagnosis of certain WHO stage 3 and 4 conditions is associated with an increased risk of mortality in those
initiating ART in RLS. This information will assist initiatives to reduce excess mortality, including prioritization of resources for
diagnostics, therapeutic interventions and research.
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Introduction
Despite increasing access to HIV treatment in resource-limited
settings (RLS), patients commencing anti-retroviral therapy (ART)
in these settings have been shown to have an increased risk of
mortality in the first months of therapy compared with those in
high-income countries [1,2], although this difference in mortality
risk reduces with time on ART [1].
A number of factors have been associated with mortality during
early ART in RLS. These include WHO clinical stage, CD4
count, body weight, anemia, male sex and lack of free access to
treatment [3–6]. Opportunistic infections have been recognized as
important causes of early mortality in those initiating ART in RLS
[7,8], but limited data are available regarding the relative impact
of specific HIV-associated conditions on mortality. Both prevalent
and incident tuberculosis (TB) have been associated with a greater
than two fold increased risk of mortality during ART in a South
African cohort [9] and cryptococcal meningitis has a high
mortality in RLS [10,11].
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Defining the relative impact of specific HIV associated
conditions on mortality during early ART will assist efforts to
reduce the excess mortality associated with this period of HIV
care by assisting program planners in strategic decision making
and prioritizing resources aimed at the prevention, diagnosis and
treatment of these conditions both before and after the initiation
of ART. The objective of this study was therefore to determine
the association between specific WHO stage 3 and 4 conditions
diagnosed after initiation of ART and all cause mortality on
ART.
Materials and Methods
Patients and Procedures
We analyzed data prospectively collected between 2002 and
2010 from patients commencing ART in 25 Me´decins Sans
Frontie`res (MSF) supported treatment programs in Democratic
Republic of Congo, Ethiopia, India, Ivory Coast, Moldova,
Myanmar, Nigeria, Republic of Congo, Zambia and Zimbabwe.
Eligible patients were not previously exposed to ART and aged
15 years and over. Eligibility criteria for ART and first-line
regimens were based on WHO guidelines [12,13] and were
generally non-nucleoside reverse-transcriptase inhibitor based. All
programs provided full blood examination, alanine transaminases
and CD4 cell count prior to ART initiation. Clinical consulta-
tions and intensive adherence counseling sessions were provided
prior to and during ART but adherence was not routinely
recorded. Daily co-trimoxazole prophylaxis was given to patients
with WHO clinical stage 2, 3 or 4 disease or those with CD4 cell
count less than 350 cells/mL. TB prophylaxis was not given
routinely. Mycobacterium avium complex (MAC) disease was
actively screened for only in Myanmar where primary prophy-
laxis was also provided with azithromycin if CD4 count was ,50
cells/mL. CD4 cell counts were monitored using automated
methods but HIV viral load testing was not routinely performed.
All care was free including ART, treatment and prophylaxis of
opportunistic infections, clinical consultations and laboratory
monitoring. Treatment sites included both hospital settings and
peripheral health clinics. Patients were considered lost to follow-
up (LFU) if they missed their next scheduled appointment by
more than 2 months.
Clinical care was provided by medical doctors and clinical
officers. Diagnosis of HIV-associated conditions was based on
WHO guidelines [12] using basic laboratory investigations
including biochemistry, haematology, sputum microscopy for acid
fast bacilli and gram stain, chest x-ray and India ink examination
of cerebrospinal fluid. Some sites had access to investigations such
as cryptococcal antigen tests and abdominal ultrasound but these
were not routinely available at all sites.
Treatment of opportunistic infections was based on standard-
ized MSF guidelines [14] and modified depending on availability
of appropriate drugs. Patients with cryptococcosis usually received
treatment with amphotericin B, although fluconazole was used at
lower than currently recommended doses (400 mg daily for
induction) when amphotericin B was not available. 5-flucytosine
was not available at any site. TB was treated according to WHO
guidelines [15]. Drug resistant TB could not be diagnosed or
treated at most sites. Sites did not have access to mycobacterial
culture, but clinically suspected MAC infection was able to be
treated with clarithromycin and ethambutol. Toxoplasmosis was
usually treated with co-trimoxazole and in most sites bleomycin
was available to treat Kaposi’s sarcoma. Patients with malnutrition
received therapeutic nutritional support.
At the initial consultation, information about medical history
and socio-demographic characteristics were collected. Clinical and
therapeutic information, including HIV associated conditions,
weight, and duration of follow up was recorded at subsequent
consultations. All information was collected on standard forms and
entered into a standardised electronic database. Due to a lack of
pre-ART data in a number of sites, this data was not included in
the analysis.
Statistical analysis
All analyses were performed using de-identified data. Condi-
tions newly diagnosed during the six months following ART
initiation were included in the analysis. If patients were diagnosed
with multiple HIV associated conditions they were all included,
however each condition was only included once. We used a
modified intention to treat analysis, ignoring treatment changes
and interruptions. The primary outcome of the analysis was all-
cause mortality and loss to follow-up (LFU) was a secondary
outcome.
We used a Cox proportional hazards model to identify the
factors associated with mortality during the follow up period.
Covariates included age, sex, pre-ART CD4 cell count, geo-
graphical region, weight and the occurrence of specific individual
WHO stage 3 and 4 conditions in the 6 months following ART
initiation. The multivariate model included all factors that were
associated with mortality on univariate analysis (P,0.05) and were
associated with greater than 10 deaths. Incomplete ascertainment
of height precluded the inclusion of body mass index in the
analyses. A similar model was used to identify factors associated
with being lost to follow-up, although the overall occurrence of
WHO stage 3 and 4 conditions, rather than specific conditions,
were examined as co-variates. Hazard proportionality was assessed
through analysis of scaled Schoenfeld residuals. Interactions
between model predictors were also tested.
In the setting of 7.3% LFU a competing risks extension of the
Cox models were derived to assess the impact, if any, of LFU on
the study’s ability to observe mortality.
We used Kaplan Meier survival analysis to compare survival of
those with the diagnosis of a WHO stage 3 or 4 condition within 6
months of ART initiation and those without. Time was measured
from the start of ART and was censored at date of death; date of
last recorded visit or at the program end date. STATA version 11
(StataCorp, College Station, Texas, USA) was used for the
analysis.
Ethics Statement
The study was approved by the MSF ethics review board, the
Alfred Hospital Human Research and Ethic Committee (Approval
331.09) and the Monash University Human Ethics Committee
(Approval 2010000219). A waiver of the requirement for informed
consent was granted by these review boards on the basis that the
analysis is observational, retrospective, performed on anonymous
data and will not impact on the care of patients.
Results
Baseline Characteristics
A total of 36,664 patients commenced ART for the first time
and were followed for a median of 1.26 years (IQR: 0.55 to 2.27;
Table 1). When compared to patients treated in Asia, African
participants were more likely to be female (56.1% vs. 40.4%,
P,0.001), have less advanced HIV disease, with a higher
baseline CD4 count (150 vs. 102 cells/mL, P,0.001) and be less
likely to have WHO stage 4 disease (10.9% vs. 32.8%, P,0.001).
Impact of HIV-Associated Conditions
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Mortality
There were a total of 2922 deaths during the follow-up period,
giving an overall crude mortality rate of 5.41 deaths per 100
person-years. There were 1217(41.6%) deaths during the first 3
months following ART initiation, giving a mortality rate of 17.07
per 100 person years (95% CI: 16.13 to 18.06) that fell to 0.64 per
100 person years (95% CI: 0.56 to 0.74) in the period after 24
months of therapy (Figure 1). During the first 12 months on ART
6.1% (n= 2,241) of participants died.
Predictors of Mortality
A diagnosis of any WHO stage 3 or 4 condition during the first
6 months on ART was associated with greater than 2 fold
increased risk of death on univariate analysis (HR: 2.21; 95% CI:
1.97 to 2.47; P,0.001). The Kaplan Meier survival curve
(Figure 2) shows that the majority of the excess mortality occurred
during the first six month period on ART.
General patient characteristics that were associated with
mortality on both univariate and multivariate analysis included
African region, male sex, older age and lower baseline CD4 cell
count (Table 2). Weight ,45kg was associated with increased
mortality on univariate analysis (HR: 1.57; 95% CI: 1.42 to 1.73;
P,0.001) but was not included in the multivariate model
because it caused the model to violate hazard proportionality.
Of the specific WHO stage 3 and 4 conditions, extra-pulmonary
cryptococcosis was associated with the greatest increased risk of
death on multivariate analysis (aHR: 3.54; 95% CI: 2.74 to 4.56),
followed by HIV wasting syndrome (aHR: 2.92; 95% CI: 2.21 to
3.85). The other stage 4 conditions significantly associated with
mortality on multivariate analysis were non-tuberculous myco-
bacterial infection, Pneumocystis pneumonia, cerebral toxoplasmo-
sis, oesophageal candidiasis, Kaposi’s sarcoma and extra-pulmo-
nary TB. These conditions were all associated with an
approximately 2 fold increased risk of death (aHR: 1.83 to 2.43)
Table 1. Baseline Characteristics of Participants.
Overall Africa Asia
No. participants (%) 36,664(100) 22,951(62.5) 13,073(35.7)
Median Follow-up: Years (IQR) 1.26(0.55–2.27) 1.07(0.37–2.07) 1.56(0.87–2.51)
Median age (IQR) 33(28–39) 35(28–42) 32(28–38)
Female sex (%) 18,405(50.2) 12,877(56.1) 5,278(40.4)
Median Baseline CD4 cell count (IQR)1 108(39–198) 150(92–179) 102(33–191)
WHO stage: 1 (%) 7226(19.7) 5362(23.4) 1750(13.4)
2 (%) 5765(15.7) 4498(19.6) 1326(10.14)
3 (%) 15,310 (41.8) 9415(41.0) 5667(43.3)
4 (%) 7131(19.4) 2489(10.9) 4285(32.8)
stage unknown 1,232(3.4) 1,187(5.2) 45(0.3)
1CD4 cell count available for 32,091 patients (87.5%).
doi:10.1371/journal.pone.0068445.t001
Figure 1. Mortality rates in time periods after commencement of anti-retroviral therapy.
doi:10.1371/journal.pone.0068445.g001
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except for extra-pulmonary TB which was associated with a
smaller increase in risk of death (aHR: 1.42; 95% CI: 1.12 to 1.8).
Penicilliosis was associated with increased mortality on univariate
analysis but not on multivariate analysis and chronic mucocuta-
neous herpes simplex infection was not associated with an
increased risk of death in this analysis.
WHO stage 3 conditions were less strongly associated with
mortality than the stage 4 conditions (unadjusted HR: 1.88; 95%
CI: 1.65 to 2.14 vs. HR: 3.59; 95% CI: 2.97 to 4.33). Unexplained
anemia, neutropenia or thrombocytopenia was most strongly
associated with mortality on univariate analysis (HR: 4.39; 95%
CI: 3.01 to 6.42; P,0.001), although the association was weaker in
the multivariate analysis (aHR: 1.59; 95% CI: 0.99 to 2.55;
P=0.054). Pulmonary TB, severe bacterial pneumonia and other
severe bacterial infections were also strongly associated with
mortality in univariate analyses and were associated with aHR of
1.26 to 1.49 in multivariate analyses, although only the result for
pulmonary TB was statistically significant. Oral candidiasis (aHR:
1.19; 95% CI: 1.03 to 1.36; P =0.017) was the only other WHO
stage 3 condition that remained significantly associated with
mortality on multivariate analysis.
The results of the competing risks analysis, performed to assess
the impact of LFU on the mortality analysis, were largely
consistent with the primary analysis (data not shown). There were
no differences in the conditions associated with mortality on
univariate analysis. In the multivariate analysis oral candidiasis
was no longer associated with an increased mortality (aHR: 1.12;
95% CI: 0.94–1.34; P=0.215) but pyomyositis (aHR: 1.67; 95%
CI: 1.01 to 2.78; P=0.049) and Penicilliosis Marneffei (aHR: 1.73;
95% CI: 1.03 to 2.88; P=0.037) both became significantly
associated with mortality.
Loss to follow-up
A total of 2672(7.3%) patients were LFU, giving an overall LFU
rate of 4.96 per 100 person-years (95% CI: 4.77 to 5.15). A
diagnosis of any WHO stage 4 condition, African region and lower
baseline CD4 cell were associated with increased risk of LFU on
both univariate and multivariate analysis (Table 3). Female sex
and a diagnosis of any WHO stage 3 condition were associated
with increased risk of LFU on univariate analysis but these did not
remain significant on multivariate analysis.
Discussion
Excess mortality during the early months of ART is a key driver
of divergent outcomes for people treated with ART in RLS
compared with high-income countries [1]. The 1-year mortality in
this study was comparable to that previously reported in similar
cohorts [1,4]. Previous studies have demonstrated the importance
of pre-treatment CD4 cell count, gender and age as influences of
mortality during this critical period [3,4]. In this large study of
adults and adolescents initiating ART in RLS, we have shown that
in addition to these factors, a new diagnosis of a WHO stage 3 or 4
condition more than doubled mortality during the first six months
of treatment. Mortality was more strongly associated with stage 4
than stage 3 conditions and was associated with most WHO stage
4 conditions, but only two of the WHO stage 3 conditions, namely,
pulmonary TB and oral candidiasis. This confirms the overall
value of the WHO clinical staging system after treatment
initiation.
The diagnosis of an opportunistic infection during early ART
is often considered a manifestation of immune reconstitution
disease in which the immune effects of HIV suppression result in
enhanced immune responses and ‘unmasking’ of previously
unrecognized infections [16]. A proportion of these presentations
are, however, also likely to be predominantly due to pathogen
virulence in the setting of persistent or residual immune
deficiency. It is therefore preferable to consider these clinical
presentations as ‘ART-associated’ with poorly understood, but
likely heterogeneous pathogenesis, driven by high prevalence of
infections and advanced HIV disease at time of ART initiation
[17,18].
As in most RLS, screening for opportunistic infections prior to
ART commencement in our study was predominantly on the basis
of clinical symptoms only. The protean nature of opportunistic
infection clinical presentations in the setting of advanced HIV
disease and the limited available diagnostic capacity results in
missed opportunities for prompt diagnosis and treatment of
opportunistic infections prior to ART initiation. A recent study
suggests that up to half of the TB diagnosed in the first year of
ART may actually be sub-clinical disease diagnosable prior to
ART initiation [19]. Enhanced screening for other infections prior
to commencement of ART is also likely to lead to earlier diagnosis
and treatment, which may reduce the high mortality rates
demonstrated in our study and elsewhere [1,4]. Three-quarters
of our study population initiated ART with a CD4 count below
200/mL. Reducing excess mortality during early ART will require
concerted efforts, funding and improved healthcare systems to
ensure earlier diagnosis of HIV infection and effective linkage to
care, as well as ongoing access to ART for individuals not yet
receiving treatment.
In this cohort Asian patients had a lower median CD4 count at
ART initiation and were more likely to have WHO stage 4 disease
than African patients. This is likely to represent poorer access to
ART in Myanmar during the study period and treatment
programs prioritizing available ART to patients with more
advanced disease. There are also a lower proportion of women
in the Asian cohort who may be diagnosed earlier than men due to
antenatal screening.
Despite patients having a lower median baseline CD4 count at
the start of ART in Asian programs, rates of mortality and LFU
were lower than in African programs. This could reflect higher
underlying mortality if undiagnosed infections were more
common in Africa compared with Asia, or reduced access to
quality care related to poorer health care infrastructure, fewer
qualified human resources, limited access to diagnostic tools, and
Figure 2. Kaplan-Meier survival analysis comparing those with
a diagnosis of any WHO stage 3 or 4 condition within the first 6
months after ART initiation and those without.
doi:10.1371/journal.pone.0068445.g002
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increased workload due to the higher prevalence of HIV
infection in Africa.
Extra-pulmonary cryptococcosis, predominantly cryptococcal
meningitis, was the condition most strongly associated with
mortality in this study. Fluconazole is often used to treat
cryptococcal meningitis in RLS due to its ease of use, relative
safety and availability and was often used in the clinics in this
study. However outcomes with fluconazole treatment are inferior
[20,21] and recent WHO guidelines [22] recommend combined
amphotericin and 5-flucytosine, that are either not registered,
available, affordable or feasible in many RLS [21]. Recent data
also suggests that fluconazole should be used at a dose of at least
800mg/day [21,22], which is higher than the dose of 400mg/day
generally used in RLS, including in this study. Screening for
cryptococcal disease has not been widely available in RLS, but it
has been shown that a positive serum cryptococcal antigen test
prior to commencement of ART is highly sensitive for predicting
the development of cryptococcal meningitis and that screening
those with CD4 ,100 cells/mL is a cost effective measure to
reduce cryptococcal disease [23,24].
TB has previously been associated with increased mortality
during early ART in RLS [7,25]. It was seen commonly in our
study population and was associated with the greatest absolute
number of deaths. The WHO clinical staging system designates
pulmonary TB as a stage 3 condition and extra-pulmonary TB as
a stage 4 condition [26], whereas both forms of TB are designated
as category C conditions in the United States Centers for Disease
Control HIV classification system [27]. We found that during
early ART pulmonary and extra-pulmonary TB had similar
impact on mortality which was higher than that for most WHO
stage 3 conditions and lower than that for most WHO stage 4
conditions. The mortality risk associated with the condition of
extra-pulmonary TB does not, however, adequately reflect the
underlying heterogeneity of this condition. In an analysis of 769
patients with TB-HIV co-infection in Thailand, meningeal TB
was associated with increased mortality relative to pulmonary TB,
Table 2. Factors associated with mortality after initiation of ART.
Number
of Cases
Number
of deaths
Unadjusted HR
(95% CI) P-value
Adjusted HR
(95% CI) P-value
Region: Africa - 1821 1.22(1.13–1.32) ,0.001 1.30(1.20–1.41) ,0.001
Asia - 1036 1.0 1.0
Gender: Male - 1542 1.61(1.5–1.73) ,0.001 1.55(1.43–1.67) ,0.001
Female - 1380 1.0 1.0
Age (per year) - - 1.03(1.02–1.04) ,0.001 1.02(1.02–1.03) ,0.001
CD4 cell count (per 100) - - 0.71(0.68–0.74) ,0.001 0.75(0.72–0.78) ,0.001
Weight: ,45kg - 1039 1.57(1.42–1.73) ,0.001 -
45–49 kg - 626 1.03(0.93–1.15) 0.547 -
50–59kg - 574 0.70(0.63–0.78) ,0.001 -
$60kg - 678 1.0 -
WHO Stage 3 Conditions
Unexplained anemia/ neutropenia/
thrombocytopenia
84 27 4.39(3.01–6.42) ,0.001 1.59(0.99–2.55) 0.054
Severe bacterial pneumonia 239 58 2.49(1.92–3.22) ,0.001 1.31(0.99–1.74) 0.06
Other Severe bacterial infections 183 38 2.45(1.78–3.38) ,0.001 1.26(0.88–1.80) 0.212
Pulmonary TB 1436 253 2.02(1.77–2.30) ,0.001 1.49(1.30–1.70) ,0.001
Unexplained prolonged fever 203 36 1.78(1.28–2.48) 0.001 0.83(0.57–1.22) 0.348
Oral Candidiasis 1448 247 1.73(1.52–1.98) ,0.001 1.19(1.03–1.36) 0.017
Unexplained chronic diarrhoea 396 64 1.61(1.25–2.06) ,0.001 1.07(0.82–1.39) 0.626
Weight loss .10% body weight 476 68 1.55(1.22–1.97) ,0.001 1.03(0.79–1.34) 0.819
Oral hairy leukoplakia 422 57 1.31(1.00–1.69) 0.048 1.04(0.79–1.38) 0.776
WHO Stage 4 conditions
Cryptococcosis extra-pulmonary 179 72 5.19(4.11–6.55) ,0.001 3.54(2.74–4.56) ,0.001
HIV wasting syndrome 166 63 4.91(3.82–6.30) ,0.001 2.92(2.21–3.85) ,0.001
Pneumocystis jiroveci pneumonia 104 35 3.65(2.62–5.09) ,0.001 2.17(1.49–3.16) ,0.001
Kaposi’s sarcoma 84 28 3.62(2.49–5.25) ,0.001 1.84(1.19–2.84) 0.006
Toxoplasmosis of the brain 97 32 3.60(2.54–5.10) ,0.001 1.89(1.26–2.83) 0.002
Non TB mycobacteria infection 189 53 3.01(2.29–3.95) ,0.001 2.43(1.80–3.28) ,0.001
Candidiasis of the oesophagus 292 78 2.87(2.29–3.60) ,0.001 1.87(1.47–2.38) ,0.001
Penicilliosis Marneffei 74 19 2.64(1.68–4.15) ,0.001 1.16(0.65–2.06) 0.616
Extra-pulmonary TB 380 82 2.26(1.81–2.81) ,0.001 1.42(1.12–1.80) 0.004
Mucocutaneous Herpes Simplex 106 12 1.03(0.59–1.82) 0.909 -
doi:10.1371/journal.pone.0068445.t002
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but intra-abdominal, disseminated and lymphatic TB were not
[28].
Strategies to reduce the burden of TB and TB-associated
mortality are important in efforts to reduce mortality during ART.
Screening with symptoms and sputum smear microscopy both
have a low sensitivity for diagnosis of TB in patients infected with
HIV [19]. Two evaluations of WHO clinical algorithms for smear
negative TB in HIV positive patients showed adequate negative
predictive value but poor positive predictive value [29,30]. New
molecular diagnostics such as the Xpert MTB/Rif system that use
real-time polymerase chain reaction technology have been shown
to have improved sensitivity for diagnosis of smear negative disease
in patients with HIV [31] and this system is now recommended by
WHO [32], but is still not widely available.
In this study HIV wasting syndrome was associated with a
high mortality risk and is therefore a marker of significantly
reduced prognosis after ART initiation and appropriately
designated as a stage 4 condition. In settings with limited
diagnostic capacity, HIV wasting syndrome is likely to represent
a number of difficult to diagnose conditions, including TB which
may be drug resistant, MAC, cytomegalovirus infection and HIV
itself. Interestingly, in our analysis HIV wasting syndrome had a
similar association with mortality as a diagnosis of non-
tuberculous mycobacterial infection, which is often suspected to
be the cause of this syndrome. The individual components of the
HIV wasting syndrome were associated with mortality on
univariate analysis only, supporting their designation as stage 3
conditions.
In this analysis WHO stage 3 conditions were not associated
with increased mortality on multivariate analysis, except for
pulmonary TB and candidiasis. Oral candidiasis has previously
been associated with mortality in a small study from South Africa
[33]. It is possible that this condition serves as a surrogate marker
for the presence of other undiagnosed opportunistic infections and
given it is relatively common and easily diagnosed could be used
by diverse clinical cadre in primary care settings to identify
patients at increased risk for adverse outcomes. Interestingly,
unexplained neutropenia, anemia or thrombocytopenia was
strongly associated with mortality on univariate analysis but this
was of borderline statistical significance on multivariate analysis.
This may be because this condition often results from HIV
infection itself and thus the association with mortality lost statistical
significance due to the adjustment for CD4 count in the
multivariate model. Severe anemia at baseline has previously
been shown to be associated with increased mortality in patients
commencing ART [3,4,6].
In our study 7.2% of patients were considered LFU. This was
comparable to that reported at 1 year by May et al [4] in Sub-
Saharan Africa but lower than reported rates of 12–19% in other
studies in RLS [1,5]. It has previously been reported that up to
58% of patients initially considered to be lost to follow-up may
actually have died if detailed tracing is performed. [34] Using
these figures the true mortality in our population may be as high as
12%. The overall similarity in factors associated with both LFU
and mortality supports the association between these factors and
mortality, and reinforces the importance of these factors in
understanding the causes of adverse outcomes during early ART.
A competing risks analysis performed to assess the impact of LFU
on the mortality analysis showed the factors associated with
mortality remained largely the same.
In contrast to findings in this study a similar analysis performed
on data from a cohort in Europe and North America found that a
diagnosis of non-Hodgkins lymphoma and progressive multifocal
leukoencephalopathy were most strongly associated with mortality
after ART initiation in resource-rich settings [35]. The overall
mortality in this study was 3.6% over a median follow-up of 43
months, which was lower than our study and the median CD4
count at initiation of therapy was higher. This is likely to reflect
differences in the incidence of endemic pathogens [36] as well as
poorer access to both diagnostics and therapeutics in resource
limited settings.
This study has several limitations. The diagnosis of HIV
associated conditions was at the discretion of treating clinicians,
rather than according to pre-specified protocols. MSF has
standardized guidelines for diagnosis and treatment of opportu-
nistic infections, but it is likely that variable approaches to
diagnosis and treatment were taken. Some conditions such as
cytomegalovirus infection are difficult to diagnose and treat in
RLS and thus were uncommonly diagnosed. Treatment of
conditions would have also varied between sites depending on
the availability and ability to administer some therapeutic agents
such as amphotericin. Nevertheless we believe the limitations in
Table 3. Predictors of loss to follow-up after ART initiation.
Unadjusted HR (95% CI) P-value Adjusted HR (95% CI) P-value
Region: Asia 1.00 1.00
Africa 3.09(2.80–3.40) ,0.001 2.83(2.37–3.39) ,0.001
Gender: Male 1.00 1.00
Female 1.24(1.14–1.34) ,0.001 0.92(0.79–1.06) 0.248
Age: (per year) 1.00(0.99–1.01) 0.960 0.99(0.98–1.00) 0.002
CD4 count: (per 100) 0.69(0.66–0.72) ,0.001 0.74(0.68–0.80) ,0.001
Weight (kg): ,45 1.00 1.00
45–49 0.98(0.88–1,11) 0.793 1.02(0.85–1.24) 0.811
50–59 1.04(0.93–1.15) 0.510 0.88(0.72–1.07) 0.186
$60 1.27(1.14–1.41) ,0.001 0.81(0.64–1.01) 0.062
Diagnosis of WHO Stage 3
Condition
1.25(1.06–1.47) 0.007 1.21(0.91–1.60) 0.191
Diagnosis of WHO Stage 4
Condition
1.63(1.22–2.17) 0.001 1.70(1.10–2.61) 0.016
doi:10.1371/journal.pone.0068445.t003
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the provision of treatment at some sites would be representative of
difficulties seen in many other RLS. Also low body weight, which
has often been associated with mortality in people with HIV [3,4],
was associated with mortality in the univariate analysis, but had to
be excluded from the multivariate analysis for statistical reasons. It
is possible this was due to a different association between weight
and mortality in Asia compared with Africa. The lack of pre-ART
data precluded comparison of mortality rates before and after
initiation of ART, and an assessment of associations of specific
WHO conditions diagnosed pre-ART with mortality on ART.
Finally, the Asian data included in our study was derived from
programs mainly operating in Myanmar, limiting the generalisa-
bility of our findings to other settings in this region, particularly
middle-income countries. Data from a program in Moldova was
included to increase power for the primary analysis however there
were insufficient patients from Moldova to allow a meaningful
comparison of Eastern European patients with those from Africa
or Asia.
In conclusion this study has demonstrated that patients
commencing ART in RLS are exposed to a high risk of
mortality in the early ART period and that specific WHO stage
3 and 4 conditions contribute significantly to this risk.
Understanding the relative contribution of these conditions to
mortality during early ART will assist with initiatives to reduce
excess mortality during this period, including prioritization of
resources for diagnostics, treatment and research. Strategies to
reduce mortality during early ART are needed, including earlier
HIV diagnosis and linkage to care, ongoing commitment to ART
access and improved screening and treatment of opportunistic
infections.
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